Ulrich Beuers

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi request reprint Overlap syndromes
    Ulrich Beuers
    Department of Medicine II Grosshadern, Ludwig Maximilians University of Munich, Germany
    Semin Liver Dis 25:311-20. 2005
  2. ncbi request reprint Hepatic overlap syndromes
    Ulrich Beuers
    Department of Medicine II Grosshadern, Ludwig Maximilians University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    J Hepatol 42:S93-9. 2005
  3. ncbi request reprint Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis
    Ulrich Beuers
    Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany
    Nat Clin Pract Gastroenterol Hepatol 3:318-28. 2006
  4. doi request reprint Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1
    Thomas Pusl
    Department of Medicine II Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Biochem Biophys Res Commun 367:208-12. 2008
  5. doi request reprint Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver
    Gerald U Denk
    Department of Medicine II, Klinikum Groshadern, University of Munich, Munich, Germany
    Hepatology 52:1758-68. 2010
  6. ncbi request reprint Phosphatidylinositol 3-kinase-dependent signaling modulates taurochenodeoxycholic acid-induced liver injury and cholestasis in perfused rat livers
    Christian Rust
    Department of Medicine II, Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Am J Physiol Gastrointest Liver Physiol 289:G88-94. 2005
  7. ncbi request reprint Ursodeoxycholic acid treatment of vanishing bile duct syndromes
    Thomas Pusl
    Department of Medicine II, Klinikum Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany
    World J Gastroenterol 12:3487-95. 2006
  8. ncbi request reprint The human transcription factor AP-1 is a mediator of bile acid-induced liver cell apoptosis
    Carina Bernt
    Department of Medicine II Grosshadern, University of Munich, Munich, Germany
    Biochem Biophys Res Commun 340:800-6. 2006
  9. doi request reprint Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent
    Christian Rust
    Department of Medicine 2, Grosshadern, University of Munich, Munich, Germany
    J Biol Chem 284:2908-16. 2009
  10. ncbi request reprint Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis
    Christian Rust
    Department of Internal Medicine II Grosshadern, University of Munich, Munich, Germany
    Clin Rev Allergy Immunol 28:135-45. 2005

Collaborators

Detail Information

Publications49

  1. ncbi request reprint Overlap syndromes
    Ulrich Beuers
    Department of Medicine II Grosshadern, Ludwig Maximilians University of Munich, Germany
    Semin Liver Dis 25:311-20. 2005
    ..In end-stage disease, liver transplantation is the treatment of choice...
  2. ncbi request reprint Hepatic overlap syndromes
    Ulrich Beuers
    Department of Medicine II Grosshadern, Ludwig Maximilians University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    J Hepatol 42:S93-9. 2005
  3. ncbi request reprint Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis
    Ulrich Beuers
    Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany
    Nat Clin Pract Gastroenterol Hepatol 3:318-28. 2006
    ..Different mechanisms of action could, therefore, contribute to the beneficial effect of UDCA under various cholestatic conditions...
  4. doi request reprint Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1
    Thomas Pusl
    Department of Medicine II Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Biochem Biophys Res Commun 367:208-12. 2008
    ..These data suggest that reversal of bile acid-induced AP-1 activation may be relevant for the antiapoptotic effect of TUDCA in liver cells...
  5. doi request reprint Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver
    Gerald U Denk
    Department of Medicine II, Klinikum Groshadern, University of Munich, Munich, Germany
    Hepatology 52:1758-68. 2010
    ..No apoptosis was observed in IPRL exposed to low micromolar TLCA, but equivalent antiapoptotic effects of TUDCA and TnorUDCA were observed in Ntcp-HepG2 cells exposed to TLCA...
  6. ncbi request reprint Phosphatidylinositol 3-kinase-dependent signaling modulates taurochenodeoxycholic acid-induced liver injury and cholestasis in perfused rat livers
    Christian Rust
    Department of Medicine II, Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Am J Physiol Gastrointest Liver Physiol 289:G88-94. 2005
    ..Inhibition of PI3-K markedly aggravated TCDCA-induced but not GCDCA-induced liver damage and hepatocyte apoptosis. Thus TCDCA appears to block its inherent toxicity by a PI3-K-dependent survival pathway in the intact liver...
  7. ncbi request reprint Ursodeoxycholic acid treatment of vanishing bile duct syndromes
    Thomas Pusl
    Department of Medicine II, Klinikum Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany
    World J Gastroenterol 12:3487-95. 2006
    ..Several potential mechanisms of action of UDCA have been proposed including stimulation of hepatobiliary secretion, inhibition of apoptosis and protection of cholangiocytes against toxic effects of hydrophobic bile acids...
  8. ncbi request reprint The human transcription factor AP-1 is a mediator of bile acid-induced liver cell apoptosis
    Carina Bernt
    Department of Medicine II Grosshadern, University of Munich, Munich, Germany
    Biochem Biophys Res Commun 340:800-6. 2006
    ..Thus, GCDCA-induced upregulation of AP-1-dependent genes appears important for the cytotoxicity of this bile acid...
  9. doi request reprint Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent
    Christian Rust
    Department of Medicine 2, Grosshadern, University of Munich, Munich, Germany
    J Biol Chem 284:2908-16. 2009
    ..In conclusion, caspase-6 appears to play an important regulatory role in the promotion of bile acid-induced apoptosis as part of a feedback loop...
  10. ncbi request reprint Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis
    Christian Rust
    Department of Internal Medicine II Grosshadern, University of Munich, Munich, Germany
    Clin Rev Allergy Immunol 28:135-45. 2005
    ..Of these drugs,the topical corticosteroid budesonide, together with UDCA, appears promising in the treatment of early stage PBC, but data remain insufficient to warrant use of budesonide outside of controlled studies...
  11. ncbi request reprint Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis
    Thomas Pusl
    Department of Medicine II, Klinikum Grosshadern, University of Munich, Munich, Germany
    J Hepatol 45:887-91. 2006
    ..The aim of this study was to assess the clinical efficacy of plasma separation and anion adsorption in the treatment of intractable pruritus of cholestasis...
  12. ncbi request reprint Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease
    Gustav Paumgartner
    Department of Medicine II, Klinikum Grosshadern, Marchioninistrasse15, University of Munich, 81377 Munich, Germany
    Clin Liver Dis 8:67-81, vi. 2004
    ..Through one or more of these mechanisms, UDCA slows the progression of primary biliary cirrhosis and improves a number of other cholestatic disorders...
  13. ncbi request reprint [Gallbladder and bile duct diseases]
    Christian Rust
    Medizinische Klinik II Grosshadern, Klinikum der Ludwig Maximilians Universität, Marchioninistrasse 15, 81377 Munchen
    Med Monatsschr Pharm 26:344-9. 2003
  14. pmc Intrahepatic cholestasis of pregnancy
    Thomas Pusl
    Department of Gastroenterology and Hepatology, AMC, University of Amsterdam, The Netherlands
    Orphanet J Rare Dis 2:26. 2007
    ..Delivery has been recommended in the 38th week when lung maturity has been established...
  15. ncbi request reprint Nucleosomal DNA fragments in autoimmune diseases
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Ann N Y Acad Sci 1075:318-27. 2006
    ..It remains to be clarified whether qualitative changes in nucleosomes are linked with pathogenesis and disease progression in SLE...
  16. ncbi request reprint Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation
    Florian Löhe
    Department of Surgery, Ludwig Maximilians University Munich, Klinikum Grosshadern, Munich, Germany
    Clin Transplant 21:696-701. 2007
    ..Therefore, it was the aim of this study to investigate tumor differentiation and microvascular invasion in relation to tumor number and size and their impact on survival after transplantation...
  17. ncbi request reprint Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease
    Rudolf Pihusch
    Medizinische Klinik III, Klinikum der Ludwig Maximilians Universität Grosshadern, 81377 Munchen, Germany
    J Hepatol 37:548-55. 2002
    ..We have assessed plasmatic coagulation and platelet function in patients with cholestatic and non-cholestatic liver disease...
  18. ncbi request reprint Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets
    Ulrich Beuers
    Department of Medicine II Grosshadern, Klinikum of the University of Munich, 81377 Munich, Germany
    J Biol Chem 278:17810-8. 2003
    ..These data strongly suggest that TLCA exerts cholestatic effects by PI3K- and PKCepsilon-dependent mechanisms that are reversed by tauroursodeoxycholic acid in a PI3K-independent way...
  19. ncbi request reprint Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited
    Gustav Paumgartner
    Department of Medicine II, Klinikum Grosshadern, University of Munich, Munich, Germany
    Hepatology 36:525-31. 2002
    ..Future efforts will focus on definition of additional clinical uses of UDCA, on optimized dosage regimens, as well as on further elucidation of mechanisms of action of UDCA at the molecular level...
  20. ncbi request reprint Role of mitogen-activated protein kinases in tauroursodeoxycholic acid-induced bile formation in cholestatic rat liver
    Gerald Ulrich Denk
    Department of Medicine II Grosshadern, Klinikum of the University of Munich, Munich, Germany
    Hepatol Res 38:717-26. 2008
    ..Erk 1/2 phosphorylation in liver tissue was unchanged after bile salt exposure for 70 min, but was transiently enhanced by TUDCA in IRH. Conclusion: MAPK do not mediate the anticholestatic effects of TUDCA in TLCA-induced cholestasis...
  21. ncbi request reprint Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy
    Thomas Pusl
    Department of Medicine II, Klinikum of the University of Munich Grosshadern, Munich, Germany
    Clin Rev Allergy Immunol 28:147-57. 2005
    ..This article provides treatment recommendations for the complications of cholestasis based on putative pathomechanisms and summarizes recent experimental and clinical data involving management options...
  22. ncbi request reprint Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich, 81377 Munich, Germany
    Anticancer Res 27:2041-5. 2007
    ..In consequence, serum levels of soluble MICA and MICB are frequently found to be elevated in cancer disease...
  23. ncbi request reprint Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis
    Wolfgang Hempfling
    Department of Medicine II, Klinikum Grosshadern, University of Munich, Munich, Germany
    Hepatology 38:196-202. 2003
    ..Thus, further evaluation of combined treatment with UDCA may be considered in early-stage PBC but not in cirrhotic patients with PBC...
  24. ncbi request reprint Tauroursodeoxycholic acid mobilizes alpha-PKC after uptake in human HepG2 hepatoma cells
    Helena Glasova
    Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany
    Eur J Clin Invest 32:437-42. 2002
    ..It is unclear whether TUDCA exerts its effects on alpha-PKC after carrier-mediated uptake into liver cells or by interaction with extracellular/membraneous structures...
  25. ncbi request reprint Extrahepatic manifestations of cholestasis
    Helena Glasova
    Department of Medicine II, Klinikum of the University of Munich Grosshadern, Munich, Germany
    J Gastroenterol Hepatol 17:938-48. 2002
    ..Therapeutic recommendations include regular exercise, calcium and vitamin D supplementation in late stage disease, hormone replacement therapy in postmenopausal women and bisphosphonates...
  26. ncbi request reprint Liver failure in adult Still's disease during corticosteroid treatment
    Stephan J Ott
    Department of Medicine II, Klinikum Grosshadern, Ludwig Maximillians Univerity, Munich, Germany
    Eur J Gastroenterol Hepatol 15:87-90. 2003
    ..To the best of our knowledge, this is the first case of adult Still's disease reported in which hepatic failure developed when other symptoms were well controlled by corticosteroid treatment...
  27. ncbi request reprint Predictors of premature delivery in patients with intrahepatic cholestasis of pregnancy
    Jurate Kondrackiene
    Department of Gastroenterology, Kaunas University of Medicine, Eiveniu Street 2, Kaunas 50009, Lithuania
    World J Gastroenterol 13:6226-30. 2007
    ..To evaluate the predictive value of clinical symptoms and biochemical parameters for prematurity in intrahepatic cholestasis of pregnancy (ICP)...
  28. pmc Overlap syndromes among autoimmune liver diseases
    Christian Rust
    Department of Gastroenterology and Hepatology, University of Amsterdam, Amsterdam NL 1100 DE, The Netherlands
    World J Gastroenterol 14:3368-73. 2008
    ..In end-stage disease, liver transplantation is the treatment of choice...
  29. ncbi request reprint Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis
    Ulrich Beuers
    Hepatology 44:280-1. 2006
  30. ncbi request reprint Gap junctional intercellular communication is not needed for the anticholestatic effect of tauroursodeoxycholic acid in mouse liver
    Thomas Pusl
    J Hepatol 42:604-5. 2005
  31. ncbi request reprint Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy
    Christiane Pauli-Magnus
    Department of Internal Medicine, University Hospital Zurich, Zurich Switzerland
    Pharmacogenetics 14:91-102. 2004
    ....
  32. doi request reprint High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective
    Susan N Cullen
    Gastroenterology Department, Wycombe General Hospital, High Wycombe, UK
    J Hepatol 48:792-800. 2008
    ..This pilot, randomised dose-ranging trial attempted to determine whether further enrichment of the bile acid pool with UDCA would lead to an improvement in outcome for PSC patients...
  33. ncbi request reprint Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy
    Jurate Kondrackiene
    Department of Gastroenterology, Kaunas University of Medicine, Kaunas, Lithuania
    Gastroenterology 129:894-901. 2005
    ..The aim of this randomized study was to evaluate the efficacy and safety of ursodeoxycholic acid in comparison with cholestyramine...
  34. ncbi request reprint Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver
    Frank Dombrowski
    Department of Pathology, University of Magdeburg, Magdeburg, Germany
    Lab Invest 86:166-74. 2006
    ....
  35. ncbi request reprint Pregnancy in autoimmune hepatitis: outcome and risk factors
    Christoph Schramm
    Department of Medicine I, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Am J Gastroenterol 101:556-60. 2006
    ..Autoimmune hepatitis (AIH) may influence pregnancy outcome and pregnancy may affect AIH. We aimed at analyzing the disease course in pregnant AIH patients and at identifying disease-related risk factors for adverse pregnancy outcome...
  36. ncbi request reprint Intrahepatic cholestasis of pregnancy--a heterogeneous group of pregnancy-related disorders?
    Ulrich Beuers
    Hepatology 43:647-9. 2006
  37. ncbi request reprint The diacylglycerol and protein kinase C pathways are not involved in insulin signalling in primary rat hepatocytes
    Irmelin Probst
    Institut fur Biochemie und Molekulare Zellbiologie, Georg August Universitat Gottingen, Germany
    Eur J Biochem 270:4635-46. 2003
    ..Together these results indicate that phospholipases C and D or multiple PKC isoforms are not involved in the hepatic insulin signal chain...
  38. doi request reprint Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease
    Thomas von Hahn
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Germany
    Scand J Gastroenterol 43:584-92. 2008
    ..Our objective was to analyze these two variations...
  39. ncbi request reprint BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, A 8091 Zurich, Switzerland
    Hepatology 39:779-91. 2004
    ..Although an impact of rare variants on BSEP and MDR3 function cannot be ruled out, our data do not support a strong role of BSEP and MDR3 genetic variations in the pathogenesis of PBC and PSC...
  40. ncbi request reprint Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis
    Gerald U Denk
    Liver Center, Yale University School of Medicine, New Haven, CT 06520 8019, USA
    Hepatology 39:1382-9. 2004
    ..9% of controls (P <.0005). In conclusion, obstructive cholestasis down-regulates Oct1 and impairs Oct1-mediated uptake in rat liver, suggesting that hepatic uptake of small cationic drugs may be impaired in cholestatic liver injury...
  41. ncbi request reprint UGT1A7 polymorphisms, polycyclic aromatic hydrocarbons and the development of hepatocellular cancer
    Florian Kuchenbauer
    Hepatology 40:1021. 2004
  42. ncbi request reprint No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis
    Karin Dilger
    Dr Falk Pharma GmbH, Freiburg, Germany
    Hepatology 41:595-602. 2005
    ..g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7). In conclusion, UDCA is not a relevant inducer of CYP3A enzymes in humans...
  43. ncbi request reprint Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis
    Karin Dilger
    Dr Falk Pharma GmbH, Freiburg, Germany
    Liver Int 26:285-90. 2006
    ..Recently, MDR1 gene polymorphisms have been discussed as a potential cause of glucocorticoid resistance. We tested the hypothesis that MDR1 gene polymorphisms affect absorption of oral budesonide...
  44. ncbi request reprint Cross-sectional imaging findings in congenital intestinal lymphangiectasia
    Nicolaus Holzknecht
    Department of Clinical Radiology, University Hospital of Munich, Munich, Germany
    J Comput Assist Tomogr 26:526-8. 2002
    ..This is the first report of MR findings in congenital intestinal lymphangiectasia with correlation with other imaging modalities...
  45. ncbi request reprint Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure
    Vanessa Stadlbauer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    ASAIO J 53:187-93. 2007
    ..Although both devices eliminate total bile acids to a similar extent, clearance of individual bile acids is different, leading to a slight change of the bile acid profile toward hydrophobic bile acids during Prometheus treatments...
  46. ncbi request reprint Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat
    Andreas Geier
    Department of Gastroenterology, Aachen University RWTH, Aachen, Germany
    J Hepatol 43:1021-30. 2005
    ..Alterations in hepatobiliary transporters may render fatty livers more vulnerable against various toxic insults...
  47. ncbi request reprint Decreased expression of breast cancer resistance protein in the duodenum in patients with obstructive cholestasis
    Christian Zimmermann
    Department of Clinical Pharmacology, University Hospital of Basel, Basel, Switzerland
    Digestion 74:101-8. 2006
    ..Since the drug efflux transporter breast cancer resistance protein (BCRP) is known to transport bile acids, we investigated whether duodenal BCRP expression could be altered during cholestasis...
  48. ncbi request reprint Budesonide in previously untreated autoimmune hepatitis
    Johannes Wiegand
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    Liver Int 25:927-34. 2005
    ..However, this regimen can cause numerous side effects. The aim of the present study was to evaluate budesonide as a treatment option in the induction of remission in patients with previously untreated AIH...
  49. ncbi request reprint Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury
    Carmen Lang
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Switzerland
    Pharmacogenet Genomics 17:47-60. 2007
    ..The aim of this study was therefore to describe the extent of genetic variability in ABCB11 and ABCB4 in patients with drug-induced liver injury and to in vitro functionally characterize newly detected ABCB11 mutations and polymorphisms...